Role of PPAR γ in the differentiation and function of neurons

PPAR Research

Volumn 2014, Issue , 2014, Pages

  Quintanilla, Rodrigo A ^a,b   Utreras, Elias ^c   Cabezas Opazo, Fabián A ^a  

^a UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

BRAIN INJURY; DEGENERATIVE DISEASE; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; NERVE CELL CHARACTERISTICS AND FUNCTIONS; NERVE CELL DEGENERATION; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEUROPROTECTION; NONHUMAN; PAIN; PAIN MEASUREMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION;

EID: 84925515308     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2014/768594     Document Type: Review

References (77)

1. E. D. Rosen and B. M. Spiegelman, "PPAR: a nuclear regulator of metabolism, differentiation, and cell growth," The Journal of Biological Chemistry, vol. 276, no. 41, pp. 37731-37734, 2001.
2. B. P. Kota, T. H. Huang, and B. D. Roufogalis, "An overview on biologicalmechanisms of PPARs," Pharmacological Research, vol. 51, no. 2, pp. 85-94, 2005.
3. M. Ahmadian, J. M. Suh, N. Hah et al., "PPAR signaling and metabolism: the good, the bad and the future," Nature Medicine, vol. 19, no. 5, pp. 557-566, 2013.
4. B. M. Forman, J. Chen, and R. M. Evans, "The peroxisome proliferator-Activated receptors: ligands and activators," Annals of theNew YorkAcademy of Sciences, vol. 804, pp. 266-275, 1996.
5. T. Coll, R. Rodríguez-Calvo, E. Barroso et al., "Peroxisome proliferator-Activated receptor (PPAR) /: a new potential therapeutic target for the treatment of metabolic syndrome," Current Molecular Pharmacology, vol. 2, no. 1, pp. 46-55, 2009.
6. Y. Barak, M. C. Nelson, E. S.Ong et al., "PPAR is required for placental, cardiac, and adipose tissue development," Molecular Cell, vol. 4, no. 4, pp. 585-595, 1999.
7. P. Tontonoz and B. M. Spiegelman, "Fat and beyond: the diverse biology of PPAR," Annual Review of Biochemistry, vol. 77, pp. 289-312, 2008.
8. K. K. Ryan, B. Li, B. E. Grayson, E. K. Matter, S. C.Woods, and R. J. Seeley, "A role for central nervous system PPAR- in the regulation of energy balance," Nature Medicine, vol. 17, no. 5, pp. 623-626, 2011.
9. H. Yki-Järvinen, "Thiazolidinediones," New England Journal of Medicine, vol. 351, no. 11, pp. 1106-1158, 2004.
10. D. L. Feinstein, E. Galea, V. Gavrilyuk et al., "Peroxisome proliferator-Activated receptor- agonists prevent experimental autoimmune encephalomyelitis," Annals of Neurology, vol. 51, no. 6, pp. 694-702, 2002.
11. M. Allahtavakoli, R. Moloudi, M. K. Arababadi, A. Shamsizadeh, and K. Javanmardi, "Delayed post ischemic treatment with Rosiglitazone attenuates infarct volume, neurological deficits and neutrophilia after embolic stroke in rat," Brain Research, vol. 1271, pp. 121-127, 2009.
12. D. M. McTigue, "Potential therapeutic targets for PPAR after spinal cord injury," PPAR Research, vol. 2008,Article ID 517162, 7 pages, 2008.
13. S. Villapol, A. K. Yaszemski, T. T. Logan, E. Sánchez-Lemus, J. M. Saavedra, and A. J. Symes, "Candesartan, an angiotensin II at 1-receptor blocker and PPAR- agonist, reduces lesion volume and improvesmotor andmemory function after traumatic brain injury in mice," Neuropsychopharmacology, vol. 37, no. 13, pp. 2817-2829, 2012.
14. S. Park, J. Yi, G. Miranpuri et al., "Thiazolidinedione class of peroxisome proliferator-Activated receptor agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats," The Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 1002-1012, 2007.
15. M. Kiaei, K. Kipiani, J. Chen, N. Y. Calingasan, and M. F. Beal, "Peroxisome proliferator-Activated receptor-gamma agonist extends survival in transgenicmousemodel of amyotrophic lateral sclerosis," ExperimentalNeurology, vol. 191, no. 2,pp. 331-336, 2005.
16. N. Shibata, M. Kawaguchi-Niida, T. Yamamoto, S. Toi, A. Hirano, and M. Kobayashi, "Effects of the PPAR activator pioglitazone on p38 MAP kinase and IB in the spinal cord of a transgenic mouse model of amyotrophic lateral sclerosis," Neuropathology, vol. 28, no. 4, pp. 387-398, 2008.
17. V. Benedusi, F.Martorana, L. Brambilla, A.Maggi, andD. Rossi, "The peroxisome proliferator-Activated receptor (PPAR) controls natural protective mechanisms against lipid peroxidation in amyotrophic lateral sclerosis," Journal of Biological Chemistry, vol. 287, no. 43, pp. 35899-35911, 2012.
18. M. T. Heneka, M. Sastre, L. Dumitrescu-Ozimek et al., "Acute treatment with the PPAR agonist pioglitazone and ibuprofen reduces glial inflammation and A1-42 levels in APPV717I transgenic mice," Brain, vol. 128, no. 6, pp. 1442-1453, 2005.
19. N. Nicolakakis, T. Aboulkassim, B. Ongali et al., "Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-Activated receptor agonist," The Journal of Neuroscience, vol. 28, no. 37, pp. 9287-9296, 2008.
20. E. M. Toledo and N. C. Inestrosa, "Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1?E9 mouse model of Alzheimer's disease," Molecular Psychiatry, vol. 15, no. 3, pp. 272-285, 2010.
21. L. A. Denner, J. Rodriguez-Rivera, S. J. Haidacher et al., "Cognitive enhancement with rosiglitazone links the hippocampal PPAR and ERK MAPK signaling pathways," The Journal of Neuroscience, vol. 32, no. 47, pp. 16725-16735, 2012.
22. S.Mandrekar-Colucci, J. C. Karlo, and G. E. Landreth, "Mechanisms underlying the rapid peroxisome proliferator-Activated receptor-mediated Amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease," The Journal of Neuroscience, vol. 32, no. 30, pp. 10117-10128, 2012.
23. M. N. Nenov, F. Laezza, S. J. Haidacher et al., "Cognitive enhancing treatment with a PPAR agonist normalizes dentate granule cell presynaptic function in Tg2576 APP mice," Journal of Neuroscience, vol. 34, no. 3, pp. 1028-1036, 2014.
24. M. Yamanaka, T. Ishikawa, A. Griep, D. Axt, M. P. Kummer, and M. T. Heneka, "PPAR/RXRA-induced and CD36-mediated microglial amyloid- phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice," Journal of Neuroscience, vol. 32, no. 48, pp. 17321-17331, 2012.
25. S. Takahashi, T. Ohshima, M. Hirasawa et al., "Conditional deletion of neuronal cyclin-dependent kinase 5 in developing forebrain results in microglial activation and neurodegeneration," The American Journal of Pathology, vol. 176, no. 1, pp. 320-329, 2010.
26. E. Utreras, R. Hamada, M. Prochazkova et al., "Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPAR agonist improves neuronal loss and early lethality," Journal of Neuroinflammation, vol. 11, article 28, 2014.
27. M.Dumont, C. Stack, C. Elipenahli et al., "PGC-1 overexpression exacerbates -Amyloid and tau deposition in a transgenic mouse model of Alzheimer's disease," The FASEB Journal, vol. 28, no. 4, pp. 1745-1755, 2014.
28. T. Tsunemi and A. R. La Spada, "PGC-1 at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond," Progress in Neurobiology, vol. 97, no. 2, pp. 142-151, 2012.
29. S.Mandrekar-Colucci, A. Sauerbeck, P. G. Popovich, andD. M. McTigue, "PPAR agonists as therapeutics for CNS trauma and neurological diseases," ASN Neuro, vol. 5, no. 5, 2013.
30. N. A. Victor, E. W. Wanderi, J. Gamboa et al., "Altered PPAR expression and activation after transient focal ischemia in rats," European Journal of Neuroscience, vol. 24, no. 6, pp. 1653-1663, 2006.
31. S. Sundararajan, J. L. Gamboa, N. A. Victor, E. W. Wanderi, W. D. Lust, and G. E. Landreth, "Peroxisome proliferator-Activated receptor- ligands reduce inflammation and infarction size in transient focal ischemia," Neuroscience, vol. 130, no. 3, pp. 685-696, 2005.
32. X. Zhao, R. Strong, J. Zhang et al., "Neuronal PPAR deficiency increases susceptibility to brain damage after cerebral ischemia," The Journal of Neuroscience, vol. 29, no. 19, pp. 6186-6195, 2009.
33. Q. Meng, X. Liang, P. Wang et al., "Rosiglitazone enhances the proliferation of neural progenitor cells and inhibits inflammation response after spinal cord injury," Neuroscience Letters, vol. 503, no. 3, pp. 191-195, 2011.
34. F. Xu, J. Li, W. Ni, Y. Shen, and X. Zhang, "Peroxisome proliferator-Activated receptor- agonist 15d-prostaglandin J2 mediates neuronal autophagy after cerebral ischemiareperfusion injury," PLoS ONE, vol. 8, no. 1, Article ID e55080, 2013.
35. K. Fuenzalida, R. Quintanilla, P. Ramos et al., "Peroxisome proliferator-Activated receptor up-regulates the Bcl-2 antiapoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis," The Journal of Biological Chemistry, vol. 282, no. 51, pp. 37006-37015, 2007.
36. N. C. Inestrosa, J. A. Godoy, R. A. Quintanilla, C. S. Koenig, and M. Bronfman, "Peroxisome proliferator-Activated receptor is expressed in hippocampal neurons and its activation prevents -Amyloid neurodegeneration: ole ofWnt signaling," Experimental Cell Research, vol. 304, no. 1, pp. 91-104, 2005.
37. R. S. Jope and G. V. W. Johnson, "The glamour and gloom of glycogen synthase kinase-3," Trends in Biochemical Sciences, vol. 29, no. 2, pp. 95-102, 2004.
38. N. C. Inestrosa, C.Montecinos-Oliva, and M. Fuenzalida, "Wnt signaling: role in Alzheimer disease and schizophrenia," Journal of Neuroimmune Pharmacology, vol. 7, no. 4, pp. 788-807, 2012.
39. M. J. Santos, R. A. Quintanilla, A. Toro et al., "Peroxisomal proliferation protects from -Amyloid neurodegeneration," Journal of Biological Chemistry, vol. 280, no. 49, pp. 41057-41068, 2005.
40. T.W. Jung, J. Y. Lee, W. S. Shim et al., "Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehydeinduced cytotoxicity," Biochemical and Biophysical Research Communications, vol. 340, no. 1, pp. 221-227, 2006.
41. M. A. Hernán, G. Logroscino, and L. A. Garciá Rodríguez, "A prospective study of alcoholism and the risk of Parkinson's disease," Journal of Neurology, vol. 251, no. 7, pp. VII14-VII17, 2004.
42. T.W. Jung, J. Y. Lee, W. S. Shim et al., "Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production," Journal of the Neurological Sciences, vol. 253, no. 1-2, pp. 53-60, 2007.
43. R. A. Quintanilla, Y. N. Jin, K. Fuenzalida, M. Bronfman, and G. V. W. Johnson, "Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-Activated receptor- (PPAR) in the pathogenesis of huntington disease,"TheJournal of Biological Chemistry, vol. 283, no. 37, pp. 25628-25637, 2008.
44. R. A. Quintanilla and G. V.W. Johnson, "Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease," Brain Research Bulletin, vol. 80, no. 4-5, pp. 242-247, 2009.
45. A. Almad, A. T. Lash, P. Wei, A. E. Lovett-Racke, and D. M. McTigue, "The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice," Experimental Neurology, vol. 232, no. 2, pp. 309-317, 2011.
46. S. A. Smith, F. J. May, G. R. Monteith, and S. J. Roberts-Thomson, "Activation of the peroxisome proliferator-Activated receptor- enhances cell death in cultured cerebellar granule cells," Journal of Neuroscience Research, vol. 66, no. 2, pp. 236-241, 2001.
47. M. Gold, C. Alderton, M. Zvartau-Hind et al., "Rosiglitazone monotherapy in mild-to-moderate alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study," Dementia and Geriatric Cognitive Disorders, vol. 30, no. 2, pp. 131-146, 2010.
48. M. E. Risner, A. M. Saunders, J. F. B. Altman et al., "Efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer's disease," The Pharmacogenomics Journal, vol. 6, no. 4, pp. 246-254, 2006.
49. L. Dupuis, R. Dengler, M. T. Heneka et al., "A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis," PLoS ONE, vol. 7, no. 6,Article ID e37885, 2012.
50. C. Nishijima, K. Kimoto, and Y. Arakawa, "Survival activity of troglitazone in rat motoneurones," Journal of Neurochemistry, vol. 76, no. 2, pp. 383-390, 2001.
51. nT. T. Rohn, S. M. Wong, C. W. Cotman, and D. H. Cribbs, "15-Deoxy-?12,14-prostaglandin J2, a specific ligand for peroxisome proliferator-Activated receptor-, induces neuronal apoptosis," NeuroReport, vol. 12, no. 4, pp. 839-843, 2001.
52. S. A. Smith, G. R. Monteith, N. A. Holman, J. A. Robinson, F. J. May, and S. J. Roberts-Thomson, "Effects of peroxisome proliferator-Activated receptor ligands ciglitazone and 15-deoxy-12,14-prostaglandin J2 on rat cultured cerebellar granule neuronal viability," Journal of Neuroscience Research, vol. 72, no. 6, pp. 747-755, 2003.
53. J. L. Garciá-Giménez, F. Sanchis-Gomar, and F. V. Pallardó, "Could thiazolidinediones increase the risk of heart failure in Friedreich's ataxia patients?" Movement Disorders, vol. 26, no. 5, pp. 769-771, 2011.
54. D.S.Geldmacher, T. Fritsch,M. J.McClendon, andG.Landreth, "A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with alzheimer disease," Archives of Neurology, vol. 68, no. 1, pp. 45-50, 2011.
55. K. Wada, A. Nakajima, K. Katayama et al., "Peroxisome proliferator-Activated receptor -mediated regulation of neural stem cell proliferation and differentiation," The Journal of Biological Chemistry, vol. 281, no. 18, pp. 12673-12681, 2006.
56. M. Yokoyama, Y. Nishi, Y. Miyamoto et al., "Molecular cloning of a human neuroD from a neuroblastoma cell line specifically expressed in the fetal brain and adult cerebellum," Molecular Brain Research, vol. 42, no. 1, pp. 135-139, 1996.
57. G. Esposito, C. Scuderi,M. Valenza et al., "Cannabidiol reduces A-induced neuroinflammation and promotes hippocampal neurogenesis through PPAR involvement," PLoS ONE, vol. 6, no. 12, Article ID e28668, 2011.
58. G. Miglio, L. Rattazzi, A. C. Rosa, and R. Fantozzi, "PPAR stimulation promotes neurite outgrowth in SH-SY5Y human neuroblastoma cells," Neuroscience Letters, vol. 454, no. 2, pp. 134-138, 2009.
59. A. Ghoochani, K. Shabani, M. Peymani et al., "The influence of peroxisome proliferator-Activated receptor 1 during differentiation of mouse embryonic stem cells to neural cells," Differentiation, vol. 83, no. 1, pp. 60-67, 2012.
60. K. M. Jung, K. S. Park, J. H. Oh et al., "Activation of p38 mitogen-Activated protein kinase and activator protein-1 during the promotion of neurite extension of PC-12 cells by 15-deoxy-?12,14-prostaglandin J2," Molecular Pharmacology, vol. 63, no. 3, pp. 607-616, 2003.
61. R. A. Quintanilla, J. A. Godoy, I. Alfaro et al., "Thiazolidinediones promote axonal growth through the activation of the JNK pathway," PLoS ONE, vol. 8, no. 5,Article ID e65140, 2013.
62. S. Yu, L. Levi, R. Siegel, and N. Noy, "Retinoic acid induces neurogenesis by activating both retinoic acid receptors (RARs) and peroxisome proliferator-Activated receptor / (PPAR/)," The Journal of Biological Chemistry, vol. 287, no. 50, pp. 42195-42205, 2012.
63. M. Maden, "Retinoic acid in the development, regeneration and maintenance of the nervous system," Nature Reviews Neuroscience, vol. 8, no. 10, pp. 755-765, 2007.
64. J. Brodbeck, M. E. Balestra, A. M. Saunders, A. D. Roses, R.W. Mahley, and Y. Huang, "Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 4, pp. 1343-1346, 2008.
65. S. Chang, T. R. Ma, R. D. Miranda, M. E. Balestra, R. W. Mahley, and Y. Huang, "Lipid-And receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity," Proceedings of theNational Academy of Sciences of the United States of America, vol. 102, no. 51, pp. 18694-18699, 2005.
66. W. J. Brecht, F. M. Harris, S. Chang et al., "Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice," Journal of Neuroscience, vol. 24, no. 10, pp. 2527-2534, 2004.
67. T. Maeda and S. Kishioka, "PPAR and Pain," International Review of Neurobiology, vol. 85, pp. 165-177, 2009.
68. G. Xing, L. Zhang, T. Heynen et al., "Rat PPAR? contains a CGGtriplet repeat and is prominently expressed in the thalamic nuclei," Biochemical and Biophysical Research Communications, vol. 217, no. 3, pp. 1015-1025, 1995.
69. S. Park, J. Yi, G. Miranpuri et al., "Thiazolidinedione class of peroxisome proliferator-Activated receptor agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats," Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 1002-1012, 2007.
70. A. L. B. Ambrosio, S. M. G. Dias, I. Polikarpov, R. B. Zurier, S. H. Burstein, and R. C. Garratt, "Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-Activated receptor ," Journal of Biological Chemistry, vol. 282, no.25, pp. 18625-18633, 2007.
71. S. B.Churi,O. S.Abdel-Aleem, K. K. Tumber,H. Scuderi-Porter, and B. K. Taylor, "Intrathecal rosiglitazone acts at peroxisome proliferator-Activated receptor- to rapidly inhibit neuropathic pain in rats," Journal of Pain, vol. 9, no. 7, pp. 639-649, 2008.
72. J.Morgenweck, R. B. Griggs, R. R.Donahue, J. E. Zadina, and B. K. Taylor, "PPAR activation blocks development and reduces established neuropathic pain in rats," Neuropharmacology, vol. 70, pp. 236-246, 2013.
73. T.Maeda, N. Kiguchi, Y. Kobayashi, M. Ozaki, and S. Kishioka, "Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury," Journal of Pharmacological Sciences, vol. 108, no. 3, pp. 341-347, 2008.
74. J. Morgenweck, O. S. Abdel-Aleem, K. C. McNamara, R. R. Donahue, M. Z. Badr, and B. K. Taylor, "Activation of peroxisome proliferator-Activated receptor in brain inhibits inflammatory pain, dorsal horn expression of Fos, and local edema," Neuropharmacology, vol. 58, no. 2, pp. 337-345, 2010.
75. J.Dill, A. R. Patel, X. Yang,R.Bachoo, C.M. Powell, and S. Li, "A molecularmechanismfor ibuprofen-mediated RhoA inhibition in neurons," Journal of Neuroscience, vol. 30, no. 3, pp. 963-972, 2010.
76. M. Hasegawa-Moriyama, T. Ohnou, K. Godai, T. Kurimoto,M. Nakama, and Y. Kanmura, "Peroxisome proliferator-Activated receptor-gamma agonist rosiglitazone attenuates postincisional pain by regulating macrophage polarization," Biochemical and Biophysical Research Communications, vol. 426, no. 1, pp. 76-82, 2012.
77. M. Hasegawa-Moriyama, T. Kurimoto, M. Nakama et al., "Peroxisome proliferator-Activated receptor-gamma agonist rosiglitazone attenuates inflammatory pain through the induction of heme oxygenase-1 in macrophages," Pain, vol. 154, no. 8, pp. 1402-1412, 2013.